Further validation using matched tumor samples confirmed decreased levels of tumor-infiltrating lymphocytes, CD4+ and CD8+ T cells, elevated M2 macrophages, and higher programmed death-ligand 1 (PD-L1) expression in the IMPC group. The gene discussed is CD4; the disease is neoplasm.